<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02276651</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT02276651</nct_id>
  </id_info>
  <brief_title>Observational Trial of a Therapeutic Platelet Transfusion Regimen</brief_title>
  <official_title>A Prospective Multicenter Observational Trial of a Therapeutic Platelet Transfusion Regimen for Patients With Acute Myeloid Leukemia in Consolidation Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum Nürnberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Chemnitz gGmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Klinikum Nürnberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Application of a therapeutic platelet transfusion Regimen in patients with acute myeloid
      leukemia in complete Remission (consolidation therapy)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the participants a therapeutic regimen for platelet transfusions will be applied: for
      clinically stable patients platelet Transfusion will be given in case of bleeding WHO II° or
      higher, for clinically instable patients platelet transfusion will be given at the decretion
      of the attending physician.

      Patients with sepsis, septic shock or infections with Infiltration of organs (e.g. invasive
      aspergillosis), plasmatic coagulation disorders or sudden or increasing headache with or
      without neurologic symptoms should receive prophylactic platelet Transfusion, if their
      platelet Count is less then 10/nl. Otherwise no prophylactic platelet Transfusion will be
      given irrespective of the actual platelet Count.

      As Primary study endpoint The incidence of bleeding episodes WHO grade III an IV will be
      documented. The bleeding incidence will then be compared to a historic cohort.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient recruitment
  </why_stopped>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">June 6, 2017</completion_date>
  <primary_completion_date type="Actual">June 6, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding Grade III and IV (WHO)</measure>
    <time_frame>Patients will be followed for the phase of thrombocytopenia after chemotherapy, an expected average of about 14 days.</time_frame>
  </primary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Thrombocytopenia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute myeloid leukemia in complete remission receiving postremission
        chemotherapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myeloid leukemia in complete remission

        Exclusion Criteria:

          -  plasmatic coagulopathy

          -  history of severe bleeding complications in chemotherapy induced thrombocytopenia

          -  no increment in platelets after platelet transfusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerstin Schaefer-Eckart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Nürnberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Nurnberg</name>
      <address>
        <city>Nurnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, Mahlknecht U, Ho A, Schaich M, Kramer M, Kaufmann M, Leimer L, Schwerdtfeger R, Conradi R, Dölken G, Klenner A, Hänel M, Herbst R, Junghanss C, Ehninger G; Study Alliance Leukemia. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012 Oct 13;380(9850):1309-16. doi: 10.1016/S0140-6736(12)60689-8. Epub 2012 Aug 8.</citation>
    <PMID>22877506</PMID>
  </reference>
  <reference>
    <citation>Wandt H, Schäfer-Eckart K, Ehninger G. Prophylactic platelet transfusion. N Engl J Med. 2013 Aug 8;369(6):577. doi: 10.1056/NEJMc1307163.</citation>
    <PMID>23924012</PMID>
  </reference>
  <reference>
    <citation>Wandt H, Schaefer-Eckart K, Frank M, Birkmann J, Wilhelm M. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006 Feb;37(4):387-92.</citation>
    <PMID>16400342</PMID>
  </reference>
  <reference>
    <citation>Wandt H, Frank M, Ehninger G, Schneider C, Brack N, Daoud A, Fackler-Schwalbe I, Fischer J, Gäckle R, Geer T, Harms P, Löffler B, Ohl S, Otremba B, Raab M, Schönrock-Nabulsi P, Strobel G, Winter R, Link H. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998 May 15;91(10):3601-6.</citation>
    <PMID>9572994</PMID>
  </reference>
  <reference>
    <citation>Wandt H, Ehninger G, Gallmeier WM. New strategies for prophylactic platelet transfusion in patients with hematologic diseases. Oncologist. 2001;6(5):446-50. Review.</citation>
    <PMID>11675523</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2014</study_first_submitted>
  <study_first_submitted_qc>October 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2014</study_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum Nürnberg</investigator_affiliation>
    <investigator_full_name>Dr Kerstin Schäfer-Eckart</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

